You're signed outSign in or to get full access.
Foresite Capital Management IV, LLC
Foresite Capital Management IV, LLC is an investment fund managed by Foresite Capital, a multi-stage healthcare and life sciences investment firm headquartered in Larkspur, California. The firm was founded in 2011 and specializes in data- and science-driven strategies focusing on healthcare and life sciences companies, serving institutional investors including university endowments, pension funds, insurance companies, and foundations. Foresite Capital employs a multidisciplinary team and manages over $2 billion in assets across multiple funds. Fund IV, specifically, raised $668 million, expanding the firm's reach and expertise.
Investment Strategy
Foresite Capital Management IV employs a rigorous, data- and science-driven investment approach, funding promising businesses in areas of great unmet need within healthcare and life sciences. The firm invests in companies from seed stage through public markets, leveraging the expertise of scientists, clinicians, analysts, and engineers to derive meaningful insights from complex healthcare data. The focus is on supporting innovative therapeutics, diagnostics, and healthcare technologies through a multidisciplinary investment team.
Latest 13F Filing Activity
Foresite Capital Management IV, LLC filed their most recent 13F report on Jun 30, 2025 disclosing 6 equity positions with a total 13F market value of $124M. The fund increased holdings in Pharvaris N.V., Lyell Immunopharma, Inc., Xenon Pharmaceuticals Inc. among other positions. Foresite Capital Management IV, LLC reduced exposure to Lyell Immunopharma, Inc., Kura Oncology, Inc., Relay Therapeutics Inc. among others.
Top Holdings
Equity Positions (6)
| Ticker | Security | Weight | Market Value | Shares | Avg Cost | Price | Change (QoQ) |
|---|---|---|---|---|---|---|---|
P PHVS | Pharvaris N.V. | 62.70% | $77.6M | 4,410,581 | $25.74 | $17.60 | +$8.4M |
M MAZE | Maze Therapeutics Inc | 20.93% | $25.9M | 2,111,919 | $11.01 | $12.27 | +$2.7M |
L LYEL | Lyell Immunopharma, Inc. | 5.72% | $7.1M | 800,399 | $8.84 | $8.84 | +$7.1M |
X XENE | Xenon Pharmaceuticals Inc | 4.05% | $5.0M | 160,000 | $31.30 | $31.30 | +$5.0M |
K KURA | Kura Oncology, Inc. | 3.81% | $4.7M | 816,882 | $20.81 | $5.77 | -$2.6M |
Industry Allocation
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more